General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-30 | 2024-03 | 2.53 | N/A | N/A | N/A |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
2023-04-27 | 2023-03 | 1.73 | 1.62 | -0.11 | -6.36% |
2023-02-02 | 2022-12 | 1.83 | 2.09 | 0.26 | 14.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-14 | ALVAREZ RALPH | Director | 54.03K | Stock Award(Grant) |
2024-02-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Award(Grant) |
2024-04-14 | HEDLEY MARY LYNNE | Director | 1.58K | Stock Award(Grant) |
2024-04-14 | JOHNSON KIMBERLY H | Director | 2.63K | Stock Award(Grant) |
2024-02-15 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 98.90M | Sale |
2024-04-14 | LUCIANO JUAN R | Director | 15.68K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
1.13 | 2023-08-14 |
1.13 | 2023-05-12 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
“makes no sense”
youre right, it doesnt
JPMorgan reiterates Eli Lilly as overweight
JPMorgan said it’s bullish heading into earnings on April 30.
“More broadly on the story, LLY remains one of our favorite names in the group as we see further upside to Street estimates as Mounjaro continues to ramp and Zepbound fully launches as well as a number of additional incretin datapoints
Opportunity knocking
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle
$LLY My Nephew works here and I ask all the time for details and he only says “buy all you can uncle”
$LLY Best of Breed Bitches. Viking is phase 2 years away. We are King in 5 categories. Going much higher soon.
$LLY Numerous Approvals Any Day Now
$LLY Best of Breed in Numerous Groundbreaking Areas! Alzheimers, Weight Loss, Diabetes, Liver Disease, Heart. Best!
$LLY Best Of Breed in 5 Major Categories
$LLY You have to be an Idiot to short he with Numerous Pending FDA Approvals in Life Changing Drugs. Weight Loss, Diabetes, Fatty Liver, Alzheimer’s and more. $1,700 in a year….
Looks like someone just bought 100K of $LLY 🤩
Nancy is that you?!
$LLY Oversold here. Buying with both hands!
$LLY Only a Fool would be selling here. This stock will be $1,500+ in a year….
$LLY Shorts will be destroyed when numerous drug approvals come through soon….
$LLY Novo in stage 1. Years off. Lilly Best of Breed
$LLY , NVO Is in stage 1. Years away. Oversold